Dyne Therapeutics is dedicated to improving the lives of individuals with genetically driven neuromuscular diseases by developing therapeutics targeting muscle and the central nervous system. The company advances clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also pursuing preclinical research for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Dyne's mission is to deliver functional improvement, making a significant impact on affected individuals, families, and communities.
The Associate Director, Quantitative Pharmacology and Modeling & Simulation (M&S) is responsible for providing strategies, plans, and deliverables on pharmacology and related quantitative analytics for the advancement of programs across all stages of drug development at Dyne Therapeutics. The role involves applying quantitative modeling, including pharmacometrics, modeling based on first principles, and data mining approaches, in support of objectives and progression of drug development programs.
Dyne Therapeutics is dedicated to improving the lives of individuals with genetically driven neuromuscular diseases by developing therapeutics targeting muscle and the central nervous system. The company advances clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), while also pursuing preclinical research for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. Dyne's mission is to deliver functional improvement, making a significant impact on affected individuals, families, and communities.
CRYSTAL PHARMATECH INC